{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:24:06Z","timestamp":1787279046114,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No. 82501672"],"award-info":[{"award-number":["Grant No. 82501672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key R&D Program of Shandong Province, China","award":["Grant No. 2025CXPT133"],"award-info":[{"award-number":["Grant No. 2025CXPT133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pre-mRNA splicing is a highly precise process, and it is estimated that approximately 9%\u201311% of pathogenic variants in patients with rare genetic diseases are caused by non-coding variants that disrupt this mechanism. Developing targeted strategies to correct such splicing defects represents a promising therapeutic avenue. In this proof-of-concept study, we demonstrate the feasibility of rescuing distinct aberrant splicing patterns using tailored RNA-targeted approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We focused on two disease-causing intronic pathogenic variants in the\n                      <jats:italic>CAPN3<\/jats:italic>\n                      gene (c.1193\u2009+\u200930G\u2009&gt;\u2009A and c.1354\u2009+\u20095G\u2009&gt;\u2009A), each leading to aberrant 5\u2019 splice site selection and premature termination codons. Using a faithful cellular minigene model, we designed and evaluated two variant-specific corrective strategies: a splice-switching oligonucleotide (SSO) to block a gained cryptic donor site (c.1193\u2009+\u200930G\u2009&gt;\u2009A), which restored canonical transcript levels to approximately 75% of wild-type; and an engineered U1 snRNA with compensatory base substitutions to restore a weakened canonical 5\u2019 splice site (c.1354\u2009+\u20095G\u2009&gt;\u2009A), which increased correct splicing from ~\u200910% to nearly 60%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This work establishes a versatile therapeutic framework, providing compelling in vitro validation that precisely targeted RNA-based strategies can be successfully adapted to correct different types of splicing defects, offering a promising blueprint for the treatment of splicing-deficient genetic disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04451-x","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T08:16:12Z","timestamp":1781338572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correction of aberrant splicing caused by intronic CAPN3 pathogenic variants using RNA-targeted therapeutic strategies in limb-girdle muscular dystrophy type R1"],"prefix":"10.1186","volume":"21","author":[{"given":"Gaoyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunuo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"4451_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/cge.13544","volume":"96","author":"L Ten Dam","year":"2019","unstructured":"Ten Dam L, Frankhuizen WS, Linssen WHJP, Straathof CS, Niks EH, Faber K, et al. Autosomal recessive limb-girdle and Miyoshi muscular dystrophies in the Netherlands: The clinical and molecular spectrum of 244 patients. Clin Genet. 2019;96:126\u201333. https:\/\/doi.org\/10.1111\/cge.13544.","journal-title":"Clin Genet"},{"key":"4451_CR2","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41436-019-0544-8","volume":"21","author":"W Liu","year":"2019","unstructured":"Liu W, Pajusalu S, Lake NJ, Zhou G, Ioannidis N, Mittal P, et al. Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases. Genet Med. 2019;21:2512\u201320. https:\/\/doi.org\/10.1038\/s41436-019-0544-8.","journal-title":"Genet Med"},{"key":"4451_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awh408","volume":"128","author":"A S\u00e1enz","year":"2005","unstructured":"S\u00e1enz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain. 2005;128:732\u201342. https:\/\/doi.org\/10.1093\/brain\/awh408.","journal-title":"Brain"},{"key":"4451_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.14670\/HH-18-929","volume":"40","author":"C-C Sun","year":"2025","unstructured":"Sun C-C, Xiao J-L, Zhao Z, Liu H-Y, Tang C-F. Recent insights into limb-girdle muscular dystrophy: Impacts, therapy, and challenges. Histol Histopathol. 2025;40:1927\u201339. https:\/\/doi.org\/10.14670\/HH-18-929.","journal-title":"Histol Histopathol"},{"key":"4451_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/jmg.2004.028738","volume":"42","author":"G Piluso","year":"2005","unstructured":"Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia VM, et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet. 2005;42:686\u201393. https:\/\/doi.org\/10.1136\/jmg.2004.028738.","journal-title":"J Med Genet"},{"key":"4451_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jmedgenet-2020-107159","volume":"58","author":"H Zhong","year":"2021","unstructured":"Zhong H, Zheng Y, Zhao Z, Lin P, Xi J, Zhu W, et al. Molecular landscape of CAPN3 mutations in limb-girdle muscular dystrophy type R1: from a Chinese multicentre analysis to a worldwide perspective. J Med Genet. 2021;58:729\u201336. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107159.","journal-title":"J Med Genet"},{"issue":"6","key":"4451_CR7","doi-asserted-by":"publisher","first-page":"e70545","DOI":"10.1002\/mco2.70545","volume":"2025","author":"Z-M Zhu","year":"2020","unstructured":"Zhu Z-M, Wu X-M, Hu Y, Bian X-L, Wang Y-Q, Zhu Q-N. Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets. MedComm. 2020;2025(6):e70545. https:\/\/doi.org\/10.1002\/mco2.70545.","journal-title":"MedComm"},{"key":"4451_CR8","doi-asserted-by":"publisher","unstructured":"Mattioli K, Bulyk ML. Beyond the gene: decoding alternative isoforms. Trends Genet. 2025;S0168-9525(25)00285-9. https:\/\/doi.org\/10.1016\/j.tig.2025.11.003.","DOI":"10.1016\/j.tig.2025.11.003"},{"key":"4451_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s44318-025-00666-z","author":"CE Hunter","year":"2026","unstructured":"Hunter CE, Xing Y. The splice of life: how alternative splicing shapes regulatory and phenotypic evolution. EMBO J. 2026. https:\/\/doi.org\/10.1038\/s44318-025-00666-z.","journal-title":"EMBO J"},{"key":"4451_CR10","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1038\/s41594-025-01724-0","volume":"32","author":"ET Abshire","year":"2025","unstructured":"Abshire ET, Maquat LE. Gene regulation through exon junction complex modularity. Nat Struct Mol Biol. 2025;32:2387\u201397. https:\/\/doi.org\/10.1038\/s41594-025-01724-0.","journal-title":"Nat Struct Mol Biol"},{"key":"4451_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrm3742","volume":"15","author":"AG Matera","year":"2014","unstructured":"Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 2014;15:108\u201321. https:\/\/doi.org\/10.1038\/nrm3742.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4451_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4161\/rna.7.2.11207","volume":"7","author":"J Karijolich","year":"2010","unstructured":"Karijolich J, Yu Y-T. Spliceosomal snRNA modifications and their function. RNA Biol. 2010;7:192. https:\/\/doi.org\/10.4161\/rna.7.2.11207.","journal-title":"RNA Biol"},{"key":"4451_CR13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/hep.27620","volume":"61","author":"WL Van Der Woerd","year":"2015","unstructured":"Van Der Woerd WL, Mulder J, Pagani F, Beuers U, Houwen RHJ, Van De Graaf SFJ. Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. Hepatology. 2015;61:1382\u201391. https:\/\/doi.org\/10.1002\/hep.27620.","journal-title":"Hepatology"},{"key":"4451_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s10038-018-0427-x","volume":"63","author":"D Scalet","year":"2018","unstructured":"Scalet D, Sacchetto C, Bernardi F, Pinotti M, van de Graaf SFJ, Balestra D. The Somatic FAH c.1061C\u2009>\u2009A Change Counteracts the Frequent FAH c.1062\u2009+\u20095G\u2009>\u2009A Mutation and Permits U1snRNA-Based Splicing Correction. J Hum Genet. 2018;63:683\u20136. https:\/\/doi.org\/10.1038\/s10038-018-0427-x.","journal-title":"J Hum Genet"},{"key":"4451_CR15","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms20174130","volume":"20","author":"D Balestra","year":"2019","unstructured":"Balestra D, Giorgio D, Bizzotto M, Fazzari M, Ben Zeev B, Pinotti M, et al. Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy. Int J Mol Sci. 2019;20:4130. https:\/\/doi.org\/10.3390\/ijms20174130.","journal-title":"Int J Mol Sci"},{"key":"4451_CR16","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/humu.24116","volume":"41","author":"S Doneg\u00e0","year":"2020","unstructured":"Doneg\u00e0 S, Rogalska ME, Pianigiani G, Igreja S, Amaral MD, Pagani F. Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs. Hum Mutat. 2020;41:2143\u201354. https:\/\/doi.org\/10.1002\/humu.24116.","journal-title":"Hum Mutat"},{"key":"4451_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.omtn.2021.10.019","volume":"26","author":"C J\u00fcschke","year":"2021","unstructured":"J\u00fcschke C, Klopstock T, Catarino CB, Owczarek-Lipska M, Wissinger B, Neidhardt J. Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption. Mol Ther Nucleic Acids. 2021;26:1186\u201397. https:\/\/doi.org\/10.1016\/j.omtn.2021.10.019.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4451_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/mt.2011.7","volume":"19","author":"E Glaus","year":"2011","unstructured":"Glaus E, Schmid F, Da Costa R, Berger W, Neidhardt J. Gene Therapeutic Approach Using Mutation-adapted U1 snRNA to Correct a RPGR Splice Defect in Patient-derived Cells. Mol Ther. 2011;19:936\u201341. https:\/\/doi.org\/10.1038\/mt.2011.7.","journal-title":"Mol Ther"},{"key":"4451_CR19","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1093\/nar\/gkz469","volume":"47","author":"I Donadon","year":"2019","unstructured":"Donadon I, Bussani E, Riccardi F, Licastro D, Romano G, Pianigiani G, et al. Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA. Nucleic Acids Res. 2019;47:7618\u201332. https:\/\/doi.org\/10.1093\/nar\/gkz469.","journal-title":"Nucleic Acids Res"},{"key":"4451_CR20","doi-asserted-by":"publisher","first-page":"102346","DOI":"10.1016\/j.gde.2025.102346","volume":"92","author":"S Bakshi","year":"2025","unstructured":"Bakshi S, Isom LL. No more nonsense: evaluating poison exons as therapeutic targets in neurodevelopmental disorders. Curr Opin Genet Dev. 2025;92:102346. https:\/\/doi.org\/10.1016\/j.gde.2025.102346.","journal-title":"Curr Opin Genet Dev"},{"key":"4451_CR21","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/ijms26052270","volume":"26","author":"Y Takeshima","year":"2025","unstructured":"Takeshima Y. Expansion of Splice-Switching Therapy with Antisense Oligonucleotides. Int J Mol Sci. 2025;26:2270. https:\/\/doi.org\/10.3390\/ijms26052270.","journal-title":"Int J Mol Sci"},{"key":"4451_CR22","doi-asserted-by":"publisher","first-page":"9920230","DOI":"10.1155\/2024\/9920230","volume":"2024","author":"B Zardetto","year":"2024","unstructured":"Zardetto B, Lauffer MC, van Roon-Mom W, Aartsma-Rus A. On Behalf Of The N Collaborative null. Practical Recommendations for the Selection of Patients for Individualized Splice-Switching ASO-Based Treatments. Hum Mutat. 2024;2024:9920230. https:\/\/doi.org\/10.1155\/2024\/9920230.","journal-title":"Hum Mutat"},{"key":"4451_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","volume":"5","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child Adolesc Health. 2021;5:491\u2013500. https:\/\/doi.org\/10.1016\/S2352-4642(21)00100-0.","journal-title":"Lancet Child Adolesc Health"},{"key":"4451_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637\u201347. https:\/\/doi.org\/10.1002\/ana.23982.","journal-title":"Ann Neurol"},{"key":"4451_CR25","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94:e2270\u201382. https:\/\/doi.org\/10.1212\/WNL.0000000000009233.","journal-title":"Neurology"},{"key":"4451_CR26","doi-asserted-by":"publisher","first-page":"e200259","DOI":"10.1212\/NXG.0000000000200259","volume":"11","author":"G Wang","year":"2025","unstructured":"Wang G, Liu H, Yang G, Gu S, Yan C, Lin P. RNA Mis-Splicing Effects of Noncanonical Splicing Variants in Limb-Girdle Muscular Dystrophy Type R1\/2A. Neurol Genet. 2025;11:e200259. https:\/\/doi.org\/10.1212\/NXG.0000000000200259.","journal-title":"Neurol Genet"},{"key":"4451_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-026-04651-9","author":"Q Zhang","year":"2026","unstructured":"Zhang Q, Yang Q, Zhou X, Zhang S, Ruan Y, Luo J. A novel de novo RNF13 variant in developmental and epileptic encephalopathy 73: genotype-phenotype correlation and literature review. BMC Neurol. 2026. https:\/\/doi.org\/10.1186\/s12883-026-04651-9.","journal-title":"BMC Neurol"},{"key":"4451_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-026-09902-6","volume":"37","author":"X-C Chen","year":"2026","unstructured":"Chen X-C, Fu J-C, Zhang A, Liu Y-T, Xing S, Wang F, et al. Whole-Exome Profiling of Epstein-Barr Virus-Positive Neuroendocrine Carcinoma of the Nasopharynx. Endocr Pathol. 2026;37:6. https:\/\/doi.org\/10.1007\/s12022-026-09902-6.","journal-title":"Endocr Pathol"},{"key":"4451_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(82)90111-8","volume":"29","author":"JT Murphy","year":"1982","unstructured":"Murphy JT, Burgess RR, Dahlberg JE, Lund E. Transcription of a gene for human U1 small nuclear RNA. Cell. 1982;29:265\u201374. https:\/\/doi.org\/10.1016\/0092-8674(82)90111-8.","journal-title":"Cell"},{"key":"4451_CR30","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1182\/blood-2007-10-117440","volume":"111","author":"M Pinotti","year":"2008","unstructured":"Pinotti M, Rizzotto L, Balestra D, Lewandowska MA, Cavallari N, Marchetti G, et al. U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency. Blood. 2008;111:2681\u20134. https:\/\/doi.org\/10.1182\/blood-2007-10-117440.","journal-title":"Blood"},{"key":"4451_CR31","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.3390\/ijms20205030","volume":"20","author":"M Aung-Htut","year":"2019","unstructured":"Aung-Htut M, McIntosh C, Ham K, Pitout I, Flynn L, Greer K, et al. Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides. IJMS. 2019;20:5030. https:\/\/doi.org\/10.3390\/ijms20205030.","journal-title":"IJMS"},{"key":"4451_CR32","doi-asserted-by":"publisher","first-page":"eaaz6100","DOI":"10.1126\/scitranslmed.aaz6100","volume":"12","author":"Z Han","year":"2020","unstructured":"Han Z, Chen C, Christiansen A, Ji S, Lin Q, Anumonwo C, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020;12:eaaz6100. https:\/\/doi.org\/10.1126\/scitranslmed.aaz6100.","journal-title":"Sci Transl Med"},{"key":"4451_CR33","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1093\/hmg\/dds045","volume":"21","author":"E Fernandez Alanis","year":"2012","unstructured":"Fernandez Alanis E, Pinotti M, Dal Mas A, Balestra D, Cavallari N, Rogalska ME, et al. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum Mol Genet. 2012;21:2389\u201398. https:\/\/doi.org\/10.1093\/hmg\/dds045.","journal-title":"Hum Mol Genet"},{"key":"4451_CR34","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.ajhg.2021.06.012","volume":"108","author":"S Lombardi","year":"2021","unstructured":"Lombardi S, Leo G, Merlin S, Follenzi A, McVey JH, Maestri I, et al. Dissection of pleiotropic effects of variants in and adjacent to F8 exon 19 and rescue of mRNA splicing and protein function. Am J Hum Genet. 2021;108:1512\u201325. https:\/\/doi.org\/10.1016\/j.ajhg.2021.06.012.","journal-title":"Am J Hum Genet"},{"key":"4451_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/mds.29575","volume":"38","author":"G Wang","year":"2023","unstructured":"Wang G, Wang B, Qin Q, Yan C, Zhao Y, Lin P. Exon Skipping Caused by Noncanonical Splicing Mutation in PRDX3-Related Spinocerebellar Ataxia. Mov Disord. 2023;38:1968\u201370. https:\/\/doi.org\/10.1002\/mds.29575.","journal-title":"Mov Disord"},{"key":"4451_CR36","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.mam.2025.101416","volume":"106","author":"HD Banadaki","year":"2025","unstructured":"Banadaki HD, Garanto A, Collin RWJ. Antisense oligonucleotides for inherited retinal diseases: a comprehensive review. Mol Aspects Med. 2025;106:101416. https:\/\/doi.org\/10.1016\/j.mam.2025.101416.","journal-title":"Mol Aspects Med"},{"key":"4451_CR37","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","volume":"33","author":"L Torres-Masjoan","year":"2025","unstructured":"Torres-Masjoan L, Aguti S, Zhou H, Muntoni F. Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases. Mol Ther. 2025;33:2689\u2013704. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.038.","journal-title":"Mol Ther"},{"key":"4451_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2024.0072","volume":"35","author":"P Andersson","year":"2025","unstructured":"Andersson P, Burel SA, Estrella H, Foy J, Hagedorn PH, Harper TA, et al. Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations. Nucleic Acid Ther. 2025;35:16\u201333. https:\/\/doi.org\/10.1089\/nat.2024.0072.","journal-title":"Nucleic Acid Ther"},{"key":"4451_CR39","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.slasd.2025.100254","volume":"35","author":"H Ruan","year":"2025","unstructured":"Ruan H, Dou D, Lu J, Xiao X, Gong X, Zhang X. Off-target effects of oligonucleotides and approaches of preclinical assessments. SLAS Discov. 2025;35:100254. https:\/\/doi.org\/10.1016\/j.slasd.2025.100254.","journal-title":"SLAS Discov"},{"key":"4451_CR40","doi-asserted-by":"publisher","first-page":"106285","DOI":"10.1016\/j.nbd.2023.106285","volume":"186","author":"ADG Leit\u00e3o","year":"2023","unstructured":"Leit\u00e3o ADG, Ahammad RU, Spencer B, Wu C, Masliah E, Rissman RA. Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce \u03b1-synuclein in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2023;186:106285. https:\/\/doi.org\/10.1016\/j.nbd.2023.106285.","journal-title":"Neurobiol Dis"},{"key":"4451_CR41","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1172\/JCI131933","volume":"129","author":"EM McNally","year":"2019","unstructured":"McNally EM, Leverson BD. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides. J Clin Invest. 2019;129:4570\u20131. https:\/\/doi.org\/10.1172\/JCI131933.","journal-title":"J Clin Invest"},{"issue":"25","key":"4451_CR42","doi-asserted-by":"publisher","first-page":"01063","DOI":"10.1016\/j.ymthe.2025.12.040","volume":"S1525\u20130016","author":"X Liu","year":"2025","unstructured":"Liu X, Campos-Gomez J, Luo M, Ma J, Chen H-C, Shukla S, et al. LUNAR LNP delivery of CFTR mRNA restores channel function and improves mucociliary clearance in ferret cystic fibrosis airways. Mol Ther. 2025;S1525\u20130016(25):01063\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.040.","journal-title":"Mol Ther"},{"key":"4451_CR43","doi-asserted-by":"publisher","first-page":"10891","DOI":"10.1038\/s41467-025-65874-x","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhao M, Xie H-X, Yu H-Y, Yang J-S, Qie L-X, et al. Mitochondria-targeted gene delivery using fluorinated lipid nanoparticles to alleviate Leber\u2019s hereditary optic neuropathy. Nat Commun. 2025;16:10891. https:\/\/doi.org\/10.1038\/s41467-025-65874-x.","journal-title":"Nat Commun"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04451-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:48:19Z","timestamp":1787276899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04451-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4451"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04451-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Qilu Hospital, Shandong University, China. Informed consent was obtained from all patients for the use of clinical information and materials in this research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients in our study signed consent for publication of this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"292"}}